-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gastric cancer (GC) is one of the main causes of death of cancer patients worldwide.
As a malignant tumor of digestive tract origin, GC is characterized by its complex tissue origin and strong heterogeneity.
Therefore, early diagnosis of GC is difficult.
The rapid development of precision medicine in recent years has made it possible to extend the survival time of patients with malignant tumors and even cure malignant tumors.
Nevertheless, the personalized medicine for GC patients needs to be improved and improved.
Overexpression and amplification of human epithelial growth factor receptor 2 (HER2; encoded by ERBB2) are common molecular features of GC.
Because HER2 plays a key regulatory role in its downstream RAS/RAF/MYC and PI3K-Akt signaling pathways, so far, HER2 is still the first choice for the development of targeted drugs for the treatment of advanced GC patients.
So far, a variety of HER2 targeted drugs have been developed, including HER2 antibody and its derivatives (trastuzumab and pertuzumab), tyrosine kinase inhibitors (lapatinib, niratinib and Afatinib, etc.
) and antibody-drug conjugates (ADCs) (DS-8201a, TDM1 and RC48, etc.
).
These HER2 targeted drugs can be used alone or in combination with other drugs in the clinic.
On December 14, 2020, Clinical and Translational Medicine published online the latest achievement of Peking University Professor Lin Shen’s team "Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies" [6] (
As a malignant tumor of digestive tract origin, GC is characterized by its complex tissue origin and strong heterogeneity.
Therefore, early diagnosis of GC is difficult.
The rapid development of precision medicine in recent years has made it possible to extend the survival time of patients with malignant tumors and even cure malignant tumors.
Nevertheless, the personalized medicine for GC patients needs to be improved and improved.
Overexpression and amplification of human epithelial growth factor receptor 2 (HER2; encoded by ERBB2) are common molecular features of GC.
Because HER2 plays a key regulatory role in its downstream RAS/RAF/MYC and PI3K-Akt signaling pathways, so far, HER2 is still the first choice for the development of targeted drugs for the treatment of advanced GC patients.
So far, a variety of HER2 targeted drugs have been developed, including HER2 antibody and its derivatives (trastuzumab and pertuzumab), tyrosine kinase inhibitors (lapatinib, niratinib and Afatinib, etc.
) and antibody-drug conjugates (ADCs) (DS-8201a, TDM1 and RC48, etc.
).
These HER2 targeted drugs can be used alone or in combination with other drugs in the clinic.
On December 14, 2020, Clinical and Translational Medicine published online the latest achievement of Peking University Professor Lin Shen’s team "Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies" [6] (
